White Paper: HER2+ Metastatic Breast Cancer Treatment Landscape – Current Choices, Future Possibilities
Therapeutic Landscape for Treatment of HER2+ mBC Continues to Evolve
Given the complexity of treatment choices in HER2+ mBC, Premier and Genentech partnered to understand treatment decision-making factors in this setting and to facilitate a user experience forum to explore community-based oncologists’ perceptions of the HER2+ mBC treatment landscape and decision-making approaches.
Premier conducted the web-based forum/panel discussion with six community-based oncologists (“Advisors”) with expertise in breast, head and neck cancers, as well as hematology.
Download the white paper to learn more about this discussion and treatments.
Please note that by downloading this resource you consent to sharing your job title, state, and intended use with Premier and the resource sponsor for their use and metrics reporting.